Zobrazeno 1 - 10
of 87
pro vyhledávání: '"MASARU FUKAHORI"'
Autor:
Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective stu
Externí odkaz:
https://doaj.org/article/e7f02c7dbce94342bdbac0633ca1ffca
Autor:
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in c
Externí odkaz:
https://doaj.org/article/f5f37084f80443099bd5a4c15daea257
Autor:
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated rel
Externí odkaz:
https://doaj.org/article/bc6dd35d26fe4df2aa0b662a99f00fd2
Autor:
Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori, Shiho Arima, Masaru Fukahori, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Koichi Akashi, Eishi Baba
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/10e1b3b0ad7e4fab943321b093b93e3e
Autor:
Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Taiga Otsuka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods This analysis
Externí odkaz:
https://doaj.org/article/eb35e2af95fa4d798ff5388601ac6ee0
Autor:
Naruki Higashidate, Suguru Fukahori, Shinji Ishii, Nobuyuki Saikusa, Naoki Hashizume, Yoshinori Koga, Daisuke Masui, Saki Sakamoto, Shiori Tsuruhisa, Hirotomo Nakahara, Yoshiaki Tanaka, Masaru Fukahori, Keisuke Miwa, Yoshiki Naito, Minoru Yagi
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-5 (2021)
Abstract Background Apart from Kasai’s procedure, liver transplantation (LTx) has dramatically improved the outcome of children with biliary atresia (BA). However, de novo malignancy has been reported to be one of the major causes of late mortality
Externí odkaz:
https://doaj.org/article/ee856017800144bc8b9f4760b5fb02b4
Autor:
Kota Takaki, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Yuki Zaizen, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Takuji Torimura
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 6, p 1483 (2022)
Chemolipiodolization (CL) is less invasive than transarterial chemoembolization (TACE) for managing hepatocellular carcinoma (HCC) because it helps avoid embolization. However, the treatment outcomes of percutaneous radiofrequency ablation (PRFA) wit
Externí odkaz:
https://doaj.org/article/295f8379e7ca4a96b995fb4a63aea198
Autor:
Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Ryoko Kuromatsu, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura
Publikováno v:
Cancers, Vol 13, Iss 21, p 5282 (2021)
Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin
Externí odkaz:
https://doaj.org/article/8ae148b8cb474f8ead8158db1e124ed8
Autor:
Mototsugu Matsunaga, Keisuke Miwa, Yosuke Oka, Sachiko Nagasu, Takahiko Sakaue, Masaru Fukahori, Tomoyuki Ushijima, Yoshito Akagi
Publikováno v:
Case Reports in Oncology, Vol 9, Iss 1, Pp 280-284 (2016)
Because of their rarity, there are no clear guidelines for the treatment of anal carcinomas; such tumors are normally subjected to the same modalities as recommended for rectal cancer. We report a patient with anal canal mucinous adenocarcinoma, with
Externí odkaz:
https://doaj.org/article/da9227661f1a4a9ba97c93258ec6158f
Autor:
Mototsugu Matsunaga, Keisuke Miwa, Yosuke Oka, Sachiko Nagasu, Takahiko Sakaue, Masaru Fukahori, Tomoyuki Ushijima, Yoshito Akagi
Publikováno v:
Case Reports in Oncology, Vol 9, Iss 1, Pp 249-254 (2016)
Anal canal adenocarcinoma is a relatively rare malignancy without established diagnostic and treatment criteria. Case reports of chemotherapy for anal canal adenocarcinoma with distant metastasis are limited, and there is no convincing evidence for t
Externí odkaz:
https://doaj.org/article/262ea69103694fe8ae9785b3a5096035